AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago. These figures are ...

AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while ...

Shares of US pharma major AbbVie were up 6.1% at $200.96 in pre-market activity, as it announced second-quarter 2025 ...

AbbVie raised its 2025 earnings forecast after a strong Q2, despite $3 billion in deal costs tied to acquisitions of Capstan ...

Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results ...

AbbVie hiked its full-year outlook on the back of better-than-expected earnings early Thursday, sending shares of the ...

Microsoft Corp. briefly topped $4 trillion amid AI optimism. Meta Platforms Inc. jumped 11% after strong earnings. Fellow megacaps Apple Inc. and Amazon.com Inc.’s results are due after the close.

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug development. Due to developments in ...